Line Selection Guide: How MJ150-L and MJ150 Work Together from Pilot to Commercial ODF Production

Introduction

In planning ODF and solvent-based transdermal patch production lines, teams usually face three core questions: Which equipment should we start with? When should we move to a commercial line? and How do we keep process continuity during scale-up? A smart line selection strategy not only saves time and cost, but also reduces process shifts and validation risk when moving from development to commercial production.

Common Decision Pitfalls

• Using capacity as the only decision factor: Focusing only on output while ignoring the need for validation documents and traceable records during development and registration.
• Disconnected logic between pilot and commercial lines: Formulation parameters and coating/drying windows are not fully defined on the pilot line, leading to rework once the commercial line is installed.
• Equating “can produce” with “can be registered”: Overlooking the need to align batch records, audit trails, and operator training between development and commercial equipment.

Switching Timing and Inheritance Path

• Use the process window and validation readiness as the switching signal: Scale-up should be triggered by a stable process window and complete validation elements, not just by a sudden increase in orders.
• Build a unified method card and batch record framework: Define common templates covering formulation viscosity ranges, target coating thickness windows, drying logic, and how intermediate storage and packaging are linked.
• Keep people and SOPs aligned: Once SOPs are established on the MJ150-L, moving to the MJ150 mainly becomes a matter of adjusting line speed, web width, and module configuration while keeping the same industrial logic.

HUANGHAI Line Selection Recommendations

• Development and pilot phase: Use the MJ150-L to establish formulation windows and finalize SOPs. Ensure that the record system and compliance pathway are clearly defined at this stage.
• Commercial scale-up: Switch to the MJ150 to increase capacity while preserving the same process logic and validation approach. Focus on line speed, web width, and module combinations for throughput and flexibility.
• End-to-end line planning: Plan the coating line together with downstream slitting and packaging so that the transition from “film formation” to “individual sachets” is smooth and time-efficient.

*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.

For a full overview of the certifications and compliance standards our equipment meets, see our Certifications & Compliance page.

*Designed to meet Class I Div 1 / ATEX explosion-proof standards for safe transdermal solvent handling.

Conclusion

Starting with the MJ150-L to stabilize methods and validation, then moving to the MJ150 for capacity scale-up, is a more controlled and compliant path. When process, documentation, and people are treated as one integrated system, scale-up can maintain consistency instead of introducing new variability.

Related Products

• MJ150-L ODF Film Coating Machine
• MJ150 ODF & Solvent-Based Transdermal Patch Film Making Machine
• Pharmaceutical Film Manufacturing Solutions

\n

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.